Abstract BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be
Introduction.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is the most common driver mutation in non-small-cell lung cancer (NSCLC) and is present in approximately 30% of all NSCLC patients, mainly in patients with adenocarcinoma (AC) histology. Other mutations in rat sarcoma viral oncogene homolog (RAS) gene family include mutations in Harvey rat sarcoma viral oncogene homolog (HRAS) and neuroblastoma rat sarcoma viral oncogene homolog (NRAS) but these are observed in less than 10% of the RAS mutations in NSCLC. RAS proteins circulate signals from growth receptors on the cell surface to intracellular effector pathways responsible for cell growth and proliferation. Mutations most often occur in codons 12, 13, or 61 of the RAS gene (located on chromosome 12) and result in an irreversible continuous activation of RAS protein [1] [2] [3] . Because of the critical role of RAS protein in cell proliferation, NSCLC patients with a KRAS mutation are believed to have a worse prognosis as compared with patients with a KRAS wild type (wt). The relation between KRAS mutational status and survival was first reported in 1990 [4] . Since then, a variety of studies have investigated the influence of KRAS mutational status on survival, however, even today, conflicting results are reported. It is believed that patients with a KRAS mutation do not respond to chemotherapy treatment, although at this moment, chemotherapy is the only treatment option for these patients [5] . In contrast, successful targeted agents are developed for patients with an EGFR mutation and EML4-ALK translocation [6, 7] . Few studies have investigated the effect of KRAS mutation on response to first-line chemotherapy in patients with advanced NSCLC [8] [9] [10] . These studies conclude that patients with a KRAS mutation do not have worse response to chemotherapy treatment. Though, because of the small sample size and differences in type of chemotherapy used in these studies, this finding remains open to debate. The aim of our retrospective study is to evaluate the association of KRAS mutational status with response to chemotherapy, progression-free survival (PFS), and overall survival (OS) in patients with advanced NSCLC treated with platinum-based chemotherapy as first-line treatment.
Patients and methods

Study Patients
We retrospectively selected all consecutive nonsquamous (p63-negative) NSCLC patients by 
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Immunohistochemistry
To distinguish between AC and squamous cell carcinoma and thyroid transcription factor 1 (TTF1) and p63, immunohistochemistry staining was performed on all patients, according to a previously described protocol [11] . For TTF1 clones 8G7G3/1 were used and for p63 clones 4A4 were used. A single observer scored the stained slides for intensity (0 = negative, 1 = weak, 2 = moderate, and 3 = strongly positive) and percentage of positive tumor cells with 10% increments. For each immunohistochemical stain, a total score was obtained by multiplying intensity and percentage of positive tumor cells. A score more than 240 was considered positive for p63. This threshold was chosen because it clearly delineates squamous cell carcinoma from AC differentiation [12] . For TTF1 a positive threshold of more than 30 was used, as even minor staining is associated with AC differentiation.
Mutation Analyses
Tumor tissue was manually macrodissected from serial sections guided by a hematoxylineosin-stained tissue section, on which the tumor area was marked by a pathologist. DNA was extracted and subjected to high-resolution melting and sequencing analysis for KRAS exon 2 and 3, according to routine protocol [13, 14] . The primary objective was to evaluate the difference in probability of response between patients with KRAS wt and KRAS mutation. Secondary objectives were PFS, defined as time from start of treatment till objective disease progression or death, and OS defined as the time from start of treatment till death. The relationship between KRAS mutational status and patient characteristics, type of chemotherapy treatment, or response was calculated using
Pearson's χ2 test. Kaplan-Meier curve was used to estimate the distribution of survival according to KRAS mutational status. Log-rank test was used to calculate difference in survival among the subgroups. To estimate the hazard ratio (HR), Cox regression analysis was used. In addition, analysis was performed for different types of KRAS mutation. For the latter analysis, types of KRAS mutations that had a frequency of less than 5 were clustered in one group.
Results
From the retrospective databases, 161 patients were eligible for the study. The patient characteristics are listed in Table 1 . The median age was 60 years (range, 34-83 years), 17 patients (10.3%) had a PS of more than 1. The majority of patients had stage IV disease (79%).
A total of 115 patients (71.4%) had an AC, 46 patients (29.6%) were diagnosed with NSCLC not otherwise specified favoring AC.
Treatment
According to the inclusion criteria, all patients received a platinum combination. Eighty-nine patients were treated with cisplatin, 69 patients were treated with carboplatin, and three patients received both regimens. Platinum was most frequently combined with gemcitabine (51.6%). Other partners were pemetrexed (31.1%), docetaxel (16.8%), and vinorelbine (0.6%). The median amount of chemotherapy courses was four. In total, there was one patient (0.6%) with a complete remission, 31 patients (19.3%) had a partial response (PR), 77 patients (47.8%) had a stable disease (SD), and 52 patients (30.7%) had progressive disease (PD).
KRAS mutation
KRAS mutations were present in 60 patients (37.3%), of which the majority of patients had stage IV disease (85.0%). There was no significant relationship among patient characteristics as listed in Table 1 and KRAS mutational status.
Also, there were no differences in Figure 1 . (Fig. 1) . The different types of mutation are presented in Fig. 2 (Fig. 3a) .
Median OS in patients with KRAS mutation was 7.0 months (95% CI, 3.9-10. 
Discussion
In this retrospective study of a consecutive cohort of patients, we observed no differences in response to first line platinum-based chemotherapy treatment in advanced NSCLC patients with or without a KRAS mutation. Although median OS and the 1-year survival rate was worse in patients harboring a KRAS mutation, this was not statistically significantly different. The aggressive behavior of KRAS mutation in NSCLC patients was first suggested by Slebos et al. In accordance with other studies, we found that response and PFS were not significantly worse in advanced NSCLC patients with a KRAS mutation ( Table 2) .
In a prospective trial, 62 patients with inoperable stage III or IV NSCLC were treated with mesna, ifosfamide, carboplatin, and etoposide. Sixteen patients (25.8%) had a KRAS mutation.
In three of 16 patients (19%) with a KRAS mutation there was response to treatment, compared with a response rate of 26% in KRAS-wt patients. This difference in response was not significant (p = 0.49). The PFS and OS were not significantly different in patients with KRAS wt and KRAS mutation.8 Another study evaluated mutational status and response to treatment using data of the TRIBUTE trial. This was a randomized phase III study in advanced NSCLC, comparing first-line chemotherapy with first-line chemotherapy with concurrent erlotinib. Of 274 patients, 264 had tumor material available for KRAS mutation analysis. In 55 patients (21%) a KRAS mutation was present. No differences in response were seen between KRAS mutated patients treated in the erlotinib-containing arm and the chemotherapy-only arm (8% versus 23%, respectively; p = 0.16). Also, no differences in PFS and OS were observed in patients either with, or without a KRAS mutation [9] . Recently, a study evaluated clinical outcome in advanced NSCLC patients receiving first-line chemotherapy according to EGFR and KRAS mutational status. In this study, 162 patients were treated with first-line chemotherapy. Thirty of 133 patients (22.6%) had a KRAS mutation. No difference in response to chemotherapy was found between patients with KRAS mutation or KRAS wt (25.0% versus 26.5%, respectively; p = 0.87). In patients treated with platinum-based chemotherapy (96 patients, of which 18 patients were with a KRAS mutation) there were also no differences in response (29.2% versus 30.2%, respectively; p = 0.95). The PFS and OS were comparable in patients with or without a KRAS mutation [10] . A variety of studies have investigated the prognostic role of KRAS mutational status. Unfortunately, these studies were equivocal because of differences in patient selection, stage of disease, histology, and type of treatment. In the early 1990s, KRAS mutation was reported to be a poor prognostic factor in early-stage NSCLC patients who underwent surgery [4, 15, 16] . However, in subgroup analysis of prospective studies in NSCLC, KRAS mutational status was not found to be prognostic [17, 18] . In a meta-analysis on the prognostic role of KRAS mutational status in NSCLC, reviewing 53 studies and 5216 patients, KRAS mutational status was found to be a poor prognostic factor. Patients with a KRAS mutation had a worse survival with an HR of 1.40 However, based on the studies discussed above and our findings, KRAS mutational status does not seem to have a clinically relevant impact on PFS and OS. Therefore, the value of KRAS mutational status in NSCLC as predictor of poor outcome has to be reviewed. A very interesting hypothesis is that different types of KRAS mutation are associated with different responses to chemotherapy regimens. Garassino et al. [20] described this in a study on KRASmutated NSCLC cell lines. Differences were found in three types of KRAS mutation: p.G12C, p.G12V, and p.G12D. In comparison with the WT clones, p.G12C mutation was associated with a reduced response to cisplatin, but increased sensitivity to taxol and pemetrexed, whereas p.G12V mutation showed a strong sensitivity to cisplatin, less sensitivity to pemetrexed. Cell lines harboring a p.G12D mutation showed resistance to taxol, but sensitivity to sorafenib.
Another recently published study reported poor survival in patients with KRAS p.G12C and p.G12V, treated with molecular targeted therapy compared with other types of KRAS mutation [21] . This study used data of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, in which a total of 255 patients were randomized to erlotinib, vandetanib, bexarotene, and erlotinib or sorafenib [22] . A total of 43 patients had a KRAS mutation; of these, 24 patients had a p.G12C or p.G12V mutation. KRAS mutational status was not associated with OS or PFS (p = 0.09). When KRAS mutations were clustered in p.G12C + p.G12V and others, there was a significant difference in median PFS when compared with KRAS wt (1.8, 3.4, and 2.0 months, respectively; p = 0.046). In our patient population, we could not confirm these data, but the sample size was probably too small to find relevant differences between the types of KRAS mutation. We encourage further study on type of KRAS mutation and its relation to response to chemotherapy and prognosis in a larger cohort of patients.
Conclusion
On the basis of our multicenter data presented here, we conclude that KRAS mutational status is not likely to be predictive for worse response or PFS in advanced nonsquamous NSCLC patients treated with platinum-based chemotherapy in first-line setting.
